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E ffects of Streptozotocin-Induced Diabetes and
Insulin Treatment on the Hypothalamic
Melanocortin System and Muscle Uncoupling
Protein 3 Expression in Rats
Peter J. Havel, Tina M. Hahn, Dana K. Sindelar, Denis G. Baskin, Mary F. Dallman, David S. Weigle, 
and Michael W. Schwartz
Hypothalamic melanocortins are among several neu-
ropeptides strongly implicated in the control of food
intake. Agonists for melanocortin 4 (MC-4) receptors
such as -melanocyte–stimulating hormone ( -MSH), a
product of proopiomelanocortin (POMC), reduce food
intake, whereas hypothalamic agouti-related protein
(AgRP) is a MC-4 receptor antagonist that increases
food intake. To investigate whether reduced melano-
cortin signaling contributes to hyperphagia induced by
uncontrolled diabetes, male Sprague-Dawley rats were
studied 7 days after administration of streptozotocin
(STZ) or vehicle. In addition, we wished to determine the
e ffect of diabetes on muscle uncoupling protein 3 (UCP-
3), a potential regulator of muscle energy metabolism.
STZ diabetic rats were markedly hyperglycemic (31.3 ±
1.0 mmol/l; P < 0.005) compared with nondiabetic con-
trols (9.3 ± 0.2 mmol/l). Insulin treatment partially cor-
rected the hyperglycemia (18.8 ± 2.5 mol/l; P < 0.005).
Plasma leptin was markedly reduced in STZ diabetic rats
(0.4 ± 0.1 ng/ml; P < 0.005) compared with controls
( 3 . 0 ± 0.4 ng/ml), an effect that was also partially
reversed by insulin treatment (1.8 ± 0.3 n g / m l ) .
Untreated diabetic rats were hyperphagic, consuming
40% more food (48 ± 1 g/day; P < 0.005) than controls
(34 ± 1 g/day). Hyperphagia was prevented by insulin
treatment (32 ± 2 g/day). In untreated diabetic rats,
hypothalamic POMC mRNA expression (measured by in
situ hybridization) was reduced by 80% (P < 0.005),
whereas AgRP mRNA levels were increased by 60% (P <
0.01), suggesting a marked decrease of hypothalamic
melanocortin signaling. The change in POMC, but not in
A g R P, mRNA levels was partially reversed by insulin
treatment. By comparison, the effects of diabetes to
increase hypothalamic neuropeptide Y (NPY) expres-
sion and to decrease corticotropin-releasing hormone
(CRH) expression were normalized by insulin treat-
ment, whereas the expression of mRNA encoding the
long form of the leptin receptor in the arcuate nucleus
was unaltered by diabetes or insulin treatment. UCP-3
mRNA expression in gastrocnemius muscle from dia-
betic rats was increased fourfold (P < 0.005), and the
increase was prevented by insulin treatment. The effect
of uncontrolled diabetes to decrease POMC, while
increasing AgRP gene expression, suggests that reduced
hypothalamic melanocortin signaling, along with
increased NPY and decreased CRH signaling, could con-
tribute to diabetic hyperphagia. These responses, in con-
cert with increased muscle UCP-3 expression, may also
contribute to the catabolic effects of uncontrolled dia-
betes on fuel metabolism in peripheral tissues. D i a b e t e s
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Hyperphagia (1,2) and altered fuel metabolism(3,4) are prominent features of uncontrolleddiabetes. Although the pathogenesis of diabetichyperphagia is incompletely understood, several
observations suggest a key role for reduced signaling by
insulin and leptin, hormones involved in the regulation of
energy balance via their effects on the central nervous sys-
tem (CNS) to regulate food intake and energy expenditure
(5–7). In the CNS, insulin and leptin reduce food intake, clos-
ing a negative feedback loop whereby an increase of energy
intake and expansion of the adipose depot lead to a com-
pensatory reduction of energy intake. Both hormones cir-
culate at levels proportionate to body fat stores (8–10) and
recent energy intake (10–12) in normal humans and ani-
mals, and both fall precipitously after induction of strepto-
zotocin (STZ) diabetes in rats (13,14). Insulin regulates lep-
tin production (12,15), and the fall of leptin in insulin-defi-
cient diabetes is likely to be mediated by decreased
insulin-mediated glucose metabolism in adipose tissue (16).
Diabetic hyperphagia is suppressed by administration of
low doses of insulin directly into the brain of STZ diabetic
rats (17) and by infusion of leptin at a rate that prevents cir-
culating leptin levels from decreasing after induction of
STZ diabetes in rats (18). Therefore, decreased signaling by
insulin and leptin is likely to have a causative role in this
hyperphagic response.
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A major mechanism underlying the effects of insulin and
leptin to reduce food intake involves the regulation of hypo-
thalamic neuropeptide systems (19,20). For example, cen-
tral administration of either insulin or leptin inhibits the
expression of the orexigenic neuropeptide, neuropeptide Y
(NPY) (17,21,22), and increases the hypothalamic expression
(21,22) and peptide content (23) of corticotropin-releasing
hormone (CRH), a neuropeptide that inhibits food intake
(24). Recently, the hypothalamic melanocortin system has
emerged as a potentially important target for the effects of
leptin on energy homeostasis. Central administration of
melanocortin 4 (MC-4) receptor agonists causes anorexia
(25), whereas antagonists have the opposite effect (25,26).
M o r e o v e r, proopiomelanocortin (POMC) deficiency (27),
ectopic expression of the endogenous melanocortin recep-
tor antagonist agouti (28), or genetic deletion of MC-4
receptors (29) causes marked obesity in mice, suggesting
that signaling at MC-4 receptors is critical for normal energy
homeostasis. The hypothalamic melanocortin system is reg-
ulated by leptin, since conditions associated with low lep-
tin levels, such as fasting or genetic leptin deficiency,
induce both decreased hypothalamic POMC mRNA levels
(30,31) and increased expression of agouti-related protein
(AgRP) (32), and leptin administration blocks these
responses (30,31). Increased food intake in leptin-deficient
conditions may therefore arise, at least in part, from
reduced melanocortin signaling. Because uncontrolled dia-
betes is accompanied by decreased levels of insulin and
leptin, we hypothesized that hypothalamic expression of
POMC mRNA should decrease, while AgRP gene expression
should increase. These responses could have an important
role in the pathogenesis of diabetic hyperphagia.
Uncontrolled diabetes also has marked effects on energy
metabolism in peripheral tissues, and the family of uncoupling
proteins has emerged as potential mediators of tissue-specific
changes in fuel utilization. Uncoupling protein 3 (UCP-3) is
a recently described member of this family (33,34). UCP-3 is
strongly induced in skeletal muscle during fasting (35,36).
Although the consequences of increased UCP-3 for muscle
energy metabolism remain to be elucidated, we hypothe-
sized that because uncontrolled diabetes shares many hor-
monal and metabolic responses in common with prolonged
fasting (e.g., decreased insulin and leptin levels and
increased levels of nonesterified fatty acids [NEFAs] and
ketones), animals with uncontrolled diabetes should have
increased UCP-3 expression in skeletal muscle. Therefore, in
this study, we examined and compared the expression of
mRNA encoding neuropeptides involved in energy homeo-
stasis (NPY, CRH, POMC, and AgRP) as well as the long form
of the leptin receptor in the hypothalamus (all by in situ
hybridization) and UCP-3 expression in skeletal muscle (by
Northern blot) of nondiabetic rats, rats with uncontrolled
STZ diabetes, and diabetic rats treated with insulin.
RESEARCH DESIGN AND METHODS
A n i m a l s . A total of 27 adult male Sprague-Dawley rats (Charles River, Wi l m i n g-
ton, MA) weighing 260–320 g were used for the studies. The animals were indi-
vidually housed in hanging wire cages and fed a standard commercial diet (#557;
Ralston Purina, Belmont, CA) and deionized water ad libitum. The light/dark
cycle was 12 h on and 12 h off, with lights on at 0600. Experimental protocols were
approved by the Institutional Animal Use and Care Committee of University of Cal-
ifornia, Davis, and were conducted in accordance with the National Institutes of
Health Guide for the Use and Care of Laboratory Animals.
Induction of diabetes. I n s u l i n - d e ficient diabetes was induced with subcutaneous
injections of freshly prepared STZ (Sigma, St. Louis, MO) at a dose of 40 m g / k g
in ice-cold 0.5 mol/l citrate buffer (pH 4.5). A second dose of STZ (40 mg/kg) was
administered 24 h later. This regimen produces insulin-deficient diabetes (plasma
glucose >450 mg/dl) in >95% of treated animals without inducing renal failure or
loss of animals from hypoglycemia secondary to insulin release associated with
acute B-cell destruction (37). Control animals received subcutaneous injections
of citrate buffer only.
Experimental protocol. To examine changes of hypothalamic neuropeptides and
UCP-3 after short-term (7 days) STZ diabetes, diabetes was induced with STZ in
18 rats as described above. Nine buffer-injected rats served as nondiabetic con-
trols. To examine the effects of insulin treatment designed to reduce plasma glu-
cose concentrations, at the time of the second STZ injection, nine of the diabetic
animals each received a single implant impregnated with bovine insulin (Linplant,
Toronto, Canada) placed subcutaneously through a 14-gauge needle under light
ketamine/xylazine (30/10 mg/kg, respectively) anesthesia as previously described
(13). These implants slowly release insulin (~2 U/day) for up to 40 days. The con-
trol and nine other STZ diabetic rats were sham implanted. Plasma glucose was
monitored daily from a tail blood sample (~0.5 ml) collected in a heparinized tube
(Sarstedt, Hayward, CA) during brief restraint (<2 min) in a polyethylene rodent
restraint cone. Plasma glucose was markedly elevated (>25 mmol/l) in all
untreated STZ diabetic rats.
Food intake and body weight were measured daily. After 7 days, the animals
were killed by decapitation. The brains were removed immediately and placed in
a cerebrum-down orientation on a glass microscope slide on a slab of dry ice and
covered with powdered dry ice. This method is necessary to preserve the normal
hypothalamic architecture. The liver, kidney and epididymal, retroperitoneal,
and inguinal fat depots were removed and weighed. Gastrocnemius muscle was
dissected, weighed, and frozen immediately in liquid nitrogen.
Assays and data analysis. Plasma glucose was measured by the glucose oxidase
method with a glucose analyzer, Model 2700 (Yellow Springs Instruments, Ye l l o w
Springs, OH). Plasma NEFA concentrations were measured with a kit from Wa c o
(Richmond, VA). Plasma insulin was measured by radioimmunoassay using rat
insulin standards from Novo Nordisk (Bagsvaerd, Denmark). Plasma leptin was mea-
sured with a radioimmunoassay for rat leptin with reagents from Linco Research
(St. Charles, MO) as previously described (38). Plasma corticosterone was measured
by radioimmunoassay (39) in the six rats in each group that were killed during the
first 8 h of the light cycle (i.e., prior to 1400), because plasma corticosterone levels
are level at this time but begin to increase during the last 4 h of the light cycle (40).
The intra- and interassay coefficients of variation for the assay are 4.0% and 11.2%,
r e s p e c t i v e l y, with a lower limit of detection of 0.2 ng/ml. The antibody used in the
assay does not cross-react with insulin, proinsulin, glucagon, pancreatic polypep-
tide, or somatostatin. UCP-3 expression in gastrocnemius muscle was measured in
six of the nine rats from each group by Northern blot analysis and as previously
described (36). UCP-3 expression was normalized to the expression of - a c t i n .
In situ hybridization
Tissue preparation. Brains were removed immediately after decapitation
between 0800–1200, frozen on dry ice, sectioned in a coronal plane at 14 µm with
a cryostat, mounted on RNase-free slides, and treated with 4% paraformaldehyde,
acetic anhydride, ethanol, and chloroform (22). For each probe, 3–6 slides (6–12
brain sections) that contain hypothalamus in the mid- to rostral region of the arcu-
ate nucleus (for POMC, NPY, and AgRP mRNA) or through the paraventricular
nucleus (PVN) (for CRH mRNA) were selected from each animal for hybridiza-
tion. Care was taken to insure that the sections were anatomically matched
among animals. For each study, all brain slices were concurrently prepared for
hybridization and were used in the same hybridization assay.
Hybridization procedure. Antisense oligonucleotide probes for NPY and CRH
were labeled with 33P-deoxyATP (Amersham, Arlington Heights, IL) using terminal
deoxynucleotide transferase (BRL, Bethesda, MD) and purified across NENsorb
columns (New England Nuclear, Boston, MA), as previously detailed (22). For
hybridization to POMC or AgRP mRNA, riboprobes were transcribed from cRNA
templates using [3 3P]UTP (30). The expression of the long form of the leptin
receptor (Ob–receptor-b [Ob-Rb]) in the arcuate nucleus was examined using a
riboprobe specific for the rat Ob-Rb mRNA (41,42). The hybridization signal in the
arcuate nucleus of each brain slice was determined from autoradiograms using
an MCID image analysis system (Imaging Research, St. Catherines, Ontario), as
described previously (30). Both the film density and hybridization image area were
measured, the product of which was calculated as an index of mRNA levels from
the mean of 6–12 sections per animal. The anatomical equivalence of hypothala-
mic sections among animals was obtained by selecting slides (viewed with a dark-
field stereomicroscope) with the aid of a rat brain atlas before hybridization and
verifying the anatomical identifications by staining sections with cresyl violet after
hybridization but before computer densitometry of the film images.
Statistical analysis. Statistical analyses were performed using a software pack-
age (StatView for Macintosh; Abacus, Berkeley, CA). Comparisons of means
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within a group were made with a paired t test. For comparisons between groups,
analysis of variance was used with a Dunnett’s post test. Linear regression analy-
sis was also performed. The null hypothesis of equal means was rejected at the
P = 0.05 level of significance. Data are expressed as means ± SE.
R E S U LT S
Body weight and food intake. STZ diabetic rats lost 10 g
of body weight by 7 days after the induction of diabetes,
whereas nondiabetic animals gained 31 g during this period
( Ta b l e 1). Insulin-treated diabetic rats also gained weight,
but this weight gain (13 g) was less than that of the control
animals (Ta b l e 1). Organ/tissue weights in the three groups
of animals are provided in Ta b l e 1. The weight of three fat
depots was reduced by ~50% and partially, but not com-
p l e t e l y, restored to ~80% of control by insulin treatment. The
combined weight of the left and right gastrocnemius muscles
was reduced by ~10% in untreated diabetic rats relative to con-
trol animals and was not decreased in diabetic rats treated
with insulin implants (Ta b l e 1). Diabetic rats were hyper-
phagic relative to control animals, with mean daily food
intake being increased by 43 ± 3% (P < 0.0001 vs. control;
F i g . 1). Insulin treatment of diabetic rats on average com-
pletely prevented this hyperphagia (Fig. 1), but there was a
range of food intake within the insulin-treated diabetic ani-
mals that was related to the degree of glycemic regulation (r =
0.94, P < 0.001).
Plasma hormones and metabolites. The STZ diabetic
animals were markedly hyperglycemic, with mean plasma
glucose levels of 31.3 ± 1.0 mmol/l (Fig. 2A). Treatment of
diabetic rats with insulin implants reduced, but did not nor-
malize, plasma glucose levels (Fig. 2A). Plasma NEFA s
were nearly doubled in untreated diabetic rats compared
with control animals. NEFA levels were normalized by
insulin treatment in the STZ diabetic rats that received
insulin implants (Fig. 2B). As expected, STZ-treated rats
were hypoinsulinemic, with mean plasma insulin levels 85%
below levels in control animals (Fig. 3A). In contrast, dia-
betic rats with insulin implants had plasma insulin levels
more than twice as high as control rats (Fig. 2A). Plasma lep-
tin levels were reduced by >80% in STZ diabetic rats.
Although insulin-treated diabetic rats had plasma leptin
concentrations four times higher than those in untreated dia-
betic animals, these levels remained below those in control
animals (Fig. 3B). Within the group of insulin-treated diabetic
animals, plasma leptin concentrations were correlated with
plasma insulin levels (r = 0.80; P < 0.01). Plasma cortico-
sterone was elevated fivefold in untreated STZ diabetic rats,
but it was not different from control levels in insulin-
implanted diabetic animals (Fig. 3C). 
Hypothalamic neuropeptide, leptin receptor, and
muscle UCP-3 expression. The in situ h y b r i d i z a t i o n
autoradiographic signal for NPY mRNA expression in the
arcuate nucleus of the hypothalamus was increased by 60 ±
15% (P < 0.025) in untreated STZ diabetic rats and was not
different from control levels in insulin-treated diabetic ani-
mals (Fig. 4A). In contrast, CRH expression was reduced by
30 ± 8% (P < 0.05) in the PVN of untreated diabetic rats and,
like NPY, was normalized in insulin-treated animals
( F i g . 4B). Hypothalamic POMC expression was markedly
reduced to <20% of control levels in the arcuate nuclei of
untreated diabetic rats. This reduction was partially
reversed, but not normalized, by insulin treatment of diabetic
animals (Fig. 5A). In contrast, the expression of AgRP
mRNA was increased by 69 ± 21% (P < 0.01) in the hypo-
thalamus of STZ diabetic rats, and this overexpression was
unaffected by insulin treatment of diabetic animals
( F i g . 5B). Among the nondiabetic control animals, NPY
expression was significantly correlated with the expression
of AgRP (r = 0.82; P < 0.025). The expression of the long form
of the leptin receptor (Ob-Rb) in the arcuate nucleus was not
different between nondiabetic animals and either untreated
or insulin-treated diabetic rats (Fig. 5C) .
After normalizing for -actin, the expression of UCP-3 in
gastrocnemius muscle in untreated STZ diabetic rats was
nearly four times higher than in control animals. This over-
expression of UCP-3 was not present in diabetic animals
treated with insulin (Fig. 6). Within the nondiabetic control
animals, UCP-3/ -actin was highly correlated with gastro-
cnemius muscle weight (r = 0.96; P < 0.003).
TA B L E 1
Body weight changes and tissue weights after 7 days in
nondiabetic control rats, untreated STZ diabetic rats, and
diabetic rats treated with insulin implants
S T Z
C o n t r o l I n s u l i n -
( n o n d i a b e t i c ) U n t r e a t e d t r e a t e d
n 9 9 9
Initial body weight (g) 294 ± 6 295 ± 4 294 ± 5
Final body weight (g) 324 ± 7 284 ± 5† 306 ± 8
D Body weight (g) 31 ± 3 –10 ± 3† 13 ± 3†
Liver weight (g) 13.6 ± 0.6 11.2 ± 0.3† 12.3 ± 0.7
Kidney weight (g) 2.7 ± 0.1 3.3 ± 0.1† 2.9 ± 0.1
Epididymal fat weight (g) 3.1 ± 0.2 1.8 ± 0.1† 2.6 ± 0.2
Retroperitoneal fat 2.5 ± 0.3 1.0 ± 0.1† 2.0 ± 0.2
weight (g)
Inguinal fat weight (g) 4.9 ± 0.3 2.7 ± 0.1† 3.8 ± 0.3*
Total fat weight (g) 10.5 ± 0.7 5.4 ± 0.3† 8.4 ± 0.7*
Gastrocnemius muscle 3.7 ± 0.1 3.3 ± 0.1† 3.6 ± 0.1
weight (g) 
*P < 0.05 vs. control; †P < 0.01 vs. control.
FIG. 1. Food intake 7 days after induction of diabetes in control (non -
diabetic), STZ diabetic, and STZ diabetic rats treated with subcutaneous
insulin (INS) implants ( n = 9 per group). * P < 0.05 vs. control.
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D I S C U S S I O N
A large body of literature supports the hypothesis that
reduced signaling by insulin or leptin, as would occur in
untreated diabetes, stimulates feeding behavior via changes
in the activity of hypothalamic neuropeptide-containing path-
ways. To further investigate this hypothesis, we used in situ
hybridization to measure effects of uncontrolled diabetes in
the presence or absence of insulin treatment on hypothalamic
expression of mRNA encoding neuropeptides implicated in
the control of food intake in STZ diabetic rats. Consistent with
previous reports (17,43–46), we found that uncontrolled dia-
betes increases NPY mRNA and decreases CRH mRNA lev-
els in rat hypothalamus, responses that provide a potential
explanation for increased food intake. A major new fin d i n g
of this study is that STZ diabetes reduced hypothalamic
POMC mRNA levels by 80%, while it increased AgRP gene
expression by 60%. The combination of reduced synthesis of
MC-4 receptor agonists, such as - m e l a n o c y t e – s t i m u l a t i n g
hormone ( -MSH) (contained within the POMC precursor),
and increased signaling by the MC-4 receptor antagonist
FIG. 2. Plasma glucose (A) and NEFA (B) concentrations 7 days after
induction of diabetes in control (nondiabetic), STZ diabetic, and STZ
diabetic rats treated with subcutaneous insulin (INS) implants (n =
9 per group). *P < 0.05 vs. control; **P < 0.05 vs. STZ untreated.
FIG. 3. Plasma insulin (A), leptin (B), and corticosterone (C) con-
centrations 7 days after induction of diabetes in control (nondia-
betic), STZ diabetic, and STZ diabetic rats treated with subcutaneous
insulin (INS) implants (n = 9 per group for insulin and leptin; n = 6
per group for corticosterone). *P < 0.05 vs. control; **P < 0.05 vs. STZ
u n t r e a t e d .
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AgRP suggests that a marked decrease of melanocortin sig-
naling occurs in the hypothalamus of rats with uncontrolled
diabetes. Because genetic POMC deficiency (27) and phar-
macological blockade (28) or genetic deletion (29) of MC-4
receptors increase feeding, these responses could potentially
play a major role in the pathogenesis of diabetic hyperphagia.
The effect of uncontrolled diabetes to increase food intake
may involve reduced insulin delivery to the CNS, since cen-
tral insulin administration to diabetic rats reduces the hyper-
phagic response (17). Uncontrolled diabetes also reduces
circulating leptin levels (13,14), and this decrease is likely to
contribute to diabetic hyperphagia, because replacement of
basal plasma leptin levels prevents the onset of hyperphagia
in STZ diabetic rats (18). The effect of lowered leptin to
increase appetite is supported by reports that genetic leptin
d e ficiency or receptor defects result in hyperphagia and obe-
sity in animals (7) and humans (47,48), and that reductions of
circulating leptin are linked to increased sensations of
hunger during energy restriction in human subjects (49).
FIG. 4. Hypothalamic NPY (A) and CRH (B) expression 7 days after
induction of diabetes in control (nondiabetic), STZ diabetic, and STZ
diabetic rats treated with subcutaneous insulin (INS) implants pre-
sented as a percentage of mean control levels (n = 7–9 per group). *P <
0.05 vs. control.
FIG. 5. Hypothalamic POMC (A) and AgRP (B) expression and
expression of the long form of the leptin receptor (Ob-Rb) (C) 7 days
after induction of diabetes in control (nondiabetic), STZ diabetic,
and STZ diabetic rats treated with subcutaneous insulin (INS)
implants presented as a percentage of mean control levels (n = 6–9 per
group). *P < 0.05 vs. control; **P < 0.05 vs. STZ untreated.
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In the current study, insulin was infused via a subcuta-
neously implanted pellet that slowly releases insulin into the
circulation. Despite plasma insulin levels that were elevated
compared with nondiabetic animals, the hyperglycemia
induced by STZ was only partially normalized in the insulin-
treated group. This failure to normalize plasma glucose levels
is consistent with an important role for hepatic insulin deliv-
ery in glucose homeostasis, since subcutaneously administered
insulin does not reproduce the preferential increase of insulin
concentrations within the hepatic portal vein that occurs
when insulin is secreted from the pancreas. In addition, STZ
diabetes induces a state of insulin resistance in addition to
insulin deficiency such that relatively high insulin levels are
needed to restore normal glucose homeostasis (50).
Whatever the mechanism for the failure to normalize
hyperglycemia, insulin treatment similarly failed to fully nor-
malize the reduced adipose mass and the marked
hypoleptinemia of diabetic rats. Insulin-stimulated glucose
uptake and metabolism in adipose tissue, which is a major
determinant of leptin synthesis and secretion (16), may
therefore have been only partially restored by our insulin
treatment regimen. These findings conflict with the complete
reversal of diabetic hyperphagia that occurred in the insulin-
treated group. One possible explanation is that circulating lep-
tin levels must fall to values below those achieved in the
insulin-treated group for hyperphagia to occur. Alternatively,
the incomplete normalization of plasma leptin levels may
have been counterbalanced by an effect of increased insulin
signaling in the brain to reduce food intake (5), because cir-
culating insulin levels were elevated well above control val-
ues in the insulin-treated animals.
The hypothalamic arcuate nucleus is the only area of the
mammalian forebrain that expresses the gene encoding
POMC, the melanocortin precursor. POMC neurons in this
brain area project to adjacent hypothalamic structures that
express MC-4 receptors (51,52), such as the PVN, which is a
major area for the control of food intake. In the PVN, synap-
tic release of -MSH, believed to be the principal endogenous
ligand for neuronal melanocortin receptors, appears to
reduce food intake under physiological conditions. This con-
clusion is based on the findings that administration of syn-
thetic melanocortin receptor antagonists induces a hyper-
phagic response (25,26) and on the finding that genetic dele-
tion of POMC (27) or MC-4 receptors leads to a severe form
of hyperphagic obesity in mice (29). The potential impor-
tance of the melanocortin system to human body weight reg-
ulation was emphasized by recent reports that marked obe-
sity occurs in families affected by mutation of genes encod-
ing either POMC (53) or the MC-4 receptor (54,55).
The endogenous MC-4 receptor antagonist AgRP is co-
expressed with NPY in neurons of the arcuate nucleus that
are adjacent to, but distinct from, POMC neurons (56,57)
and are activated in conditions associated with low leptin lev-
els, such as fasting (56,58). Our finding that levels of both NPY
and AgRP mRNA were elevated in diabetic animals and were
highly correlated with one another within nondiabetic control
animals supports the hypothesis that the expression of these
two neuropeptides is regulated in parallel (56). However,
insulin treatment of diabetic rats restored hypothalamic NPY
expression to control levels but did not normalize AgRP
expression. Therefore, it is possible that NPY and AgRP
expression are differentially regulated by insulin and leptin.
In this regard, it is worth noting that whereas fasting typically
increases NPY mRNA levels by two- to threefold, it increases
AgRP mRNA by 18-fold (56). In contrast, uncontrolled dia-
betes elicited comparable increases of NPY and AgRP mRNA
in the arcuate nucleus, suggesting differential regulation of
NPY and AgRP expression in the two conditions.
Genetic leptin deficiency in o b/o b mice is associated with
reduced arcuate nucleus POMC mRNA levels (30,31) and
increased AgRP mRNA levels (58), as well as with hyperpha-
gia (a scenario similar to that observed in STZ diabetes). The
hypothesis that leptin deficiency mediates these hypothalamic
responses is supported by the demonstration that leptin
administration to o b/o b mice increases arcuate nucleus POMC
mRNA levels (30,31), that leptin receptors are expressed by
POMC neurons (59), and that leptin administration to fasted
animals increases hypothalamic POMC gene expression (30)
while reducing AgRP mRNA levels (60). The effect of uncon-
trolled diabetes to lower POMC while raising AgRP mRNA lev-
els in the hypothalamus can therefore be explained, at least in
part, by reduced leptin levels. Consistent with this conclusion,
we found that insulin treatment of diabetic rats caused pro-
portionately similar increases of plasma leptin and hypothal-
amic POMC mRNA. However, insulin treatment did not nor-
malize AgRP mRNA levels in diabetic rats, suggesting that fac-
tors regulating hypothalamic AgRP gene expression in rats
with STZ diabetes differ from those that control expression of
POMC. For example, the partial normalization of plasma lep-
tin levels in the insulin-treated group may have been sufficient
to increase POMC, but not to decrease AgRP, gene expression.
A l t e r n a t i v e l y, factors in the diabetic milieu that are indepen-
dent of leptin deficiency may explain the persistent increase
of AgRP mRNA in the insulin-treated group.
An important role for reduced melanocortin signaling in the
pathogenesis of diabetic hyperphagia is challenged by the
observation that food intake was completely normalized by
insulin treatment, despite persistently reduced POMC and
increased AgRP mRNA levels in the arcuate nucleus. Factors
other than reduced melanocortin signaling are therefore
likely to contribute to diabetic hyperphagia. A number of pub-
FIG. 6. Expression of UCP-3 normalized to -actin expression (UCP-3 /
-actin) in gastrocnemius muscle 7 days after the induction of diabetes
in control (nondiabetic), STZ diabetic, and STZ diabetic rats treated
with subcutaneous insulin (INS) implants presented as a percentage
of mean control levels (n = 6 per group). *P < 0.05 vs. control.
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lished reports have demonstrated that uncontrolled diabetes
is associated with increased NPY mRNA and peptide levels in
the arcuate nucleus (17,43–46) and increased NPY peptide lev-
els in the PVN (44). In the current study, we confirmed previ-
ous reports that uncontrolled diabetes increases NPY mRNA
levels in the arcuate nucleus and that insulin treatment nor-
malizes both the increased NPY gene expression and the
hyperphagic response. Correction of increased NPY signaling
may therefore play a key role in the ability of insulin treatment
to restore food intake to normal levels in diabetic animals.
Because insulin treatment normalized elevated NPY
expression despite only a partial restoration of normal leptin
levels, it is possible that the relatively high plasma insulin con-
centration in the insulin-treated group was sufficient to off-
set the effect of persistently low leptin levels in the regulation
of NPY gene expression. In contrast, levels of mRNA encod-
ing the anorectic neuropeptide CRH were reduced in the
PVN of the untreated diabetic rats. These findings support the
hypothesis that hyperphagia in animals with uncontrolled
diabetes arises as a consequence of both increased signaling
by hypothalamic mediators that stimulate food intake (e.g.,
NPY and AgRP) and reduced signaling by peptides that cause
anorexia (e.g., melanocortins and CRH). Whereas reduced
POMC gene expression was only partially corrected, the
decline of CRH mRNA levels in the hypothalamus of dia-
betic rats was fully normalized by chronic insulin adminis-
tration. Considering that leptin increases the expression of
both POMC and CRH mRNA (22,30,31), low leptin levels may
have contributed to reduced hypothalamic CRH gene expres-
sion in uncontrolled diabetes. However, uncontrolled dia-
betes also increases circulating glucocorticoid levels (61,62),
and insulin treatment prevents this response (61). Since glu-
cocorticoids inhibit CRH gene expression by negative feed-
back, the diabetes-induced rise in glucocorticoids that we
observed may have lowered CRH gene expression. Indeed,
STZ-induced diabetes in the rat does not alter hypothalamic
CRH gene expression when adrenalectomy and glucocorti-
coid replacement are used to match glucocorticoid levels
between diabetic and nondiabetic animals (63), suggesting a
major role for increased glucocorticoids to mediate the
effects of diabetes on CRH gene expression. 
One mechanism that does not appear to mediate the
effects of uncontrolled diabetes on food intake or hypothal-
amic neuropeptide expression is a change of leptin sensitiv-
ity resulting from alterations in the expression of the leptin
receptor (Ob-Rb), since neither diabetes nor insulin treatment
affected the expression of mRNA encoding the long form of
Ob-Rb in the arcuate nucleus. This result is somewhat sur-
prising given the observations that Ob-Rb expression is
upregulated in the arcuate nucleus of o b/o b mice and in the
arcuate and ventromedial nuclei of fasted rats and is
decreased with exogenous leptin treatment (41). However,
our recent report that STZ diabetic rats exhibit normal sen-
sitivity to the anorexic action of exogenous leptin (18) is in
agreement with the observation that CNS expression of lep-
tin receptors is not altered in diabetic animals.
Uncontrolled diabetes exerts profound effects on patterns
of fuel flux and tissue fuel utilization. For example, resting
energy expenditure and muscle fatty acid oxidation (64) are
increased in STZ diabetic rats. Growing interest has focused
on the role of uncoupling proteins, such as UCP-3 (33,34), as
potential mediators of altered metabolic responses in periph-
eral tissues. Although the function of UCP-3 remains to be elu-
cidated, its expression in skeletal muscle, a major site of
metabolic fuel utilization, is markedly increased by fasting in
rats (35,36), an effect attributable in part to increased circu-
lating NEFA concentrations (36). In the current experiment,
we also found marked increases of UCP-3 mRNA in skeletal
muscle of diabetic animals, and this effect was completely pre-
vented by insulin treatment. Similar regulation of UCP-3 was
recently reported in cardiac muscle of STZ diabetic rats (65).
Because our data show that changes in plasma NEFA con-
centrations paralleled those of UCP-3 mRNA, it is possible that
delivery of this energy substrate to muscle exerts direct
effects to stimulate UCP-3 expression. Increased energy
expenditure associated with partial uncoupling of oxidative
phosphorylation in the large mass of skeletal muscle in the
body may therefore contribute to the loss of adipose tissue
that accompanies uncontrolled diabetes. Thus, the hyper-
phagia of uncontrolled diabetes is unable to compensate for
this increase in energy expenditure. In contrast to the upreg-
ulation of UCP-3 reported here, it is worth noting that the
brown adipose tissue–specific uncoupling protein UCP-1 is
decreased in unregulated STZ diabetes (66,67), an effect that
is prevented by insulin administration (66).
It is also possible that changes within the CNS induced by
uncontrolled diabetes contribute to altered UCP-3 expression
in skeletal muscle. Precedent for this hypothesis is provided
by the demonstration that intrahypothalamic infusion of NPY
suppresses UCP-1 expression (68), whereas central admin-
istration of CRH increases uncoupling activity in brown adi-
pose tissue (29). NPY also modulates insulin-stimulated glu-
cose transport in peripheral tissues, including skeletal mus-
cle (69). Since fasting and uncontrolled diabetes are both
accompanied by increased production and release of NPY and
AgRP and decreased CRH and POMC expression, it is con-
ceivable that this hypothalamic response alters autonomic
o u t flow (70), which may in turn influence the expression of
molecules such as UCP-3 (35,71). Consistent with this idea,
we found that hypothalamic NPY expression in the untreated
diabetic rats was positively correlated (r = 0.99; P < 0.0001),
and CRH expression in insulin-treated rats was inversely cor-
related (r = –0.94; P < 0.02), with muscle UCP-3 expression.
Further investigation of the role of UCP-3 in muscle energy
metabolism and its potential link to hypothalamic neu-
ropeptide signaling is warranted.
In conclusion, uncontrolled diabetes has major effects on
the hypothalamic melanocortin system (decreased POMC
and increased AgRP expression) that may contribute, in
combination with increased NPY and reduced CRH signaling,
to hyperphagia characteristic of the diabetic state. The fin d-
ings are compatible with the hypothesis that deficiencies of
insulin and leptin have potent effects on hypothalamic neu-
ropeptide systems involved in energy homeostasis, which
may in turn contribute to the marked effects of uncontrolled
diabetes on fuel utilization and skeletal muscle UCP-3 gene
e x p r e s s i o n .
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